Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of HER-2 Protein AutoVac and QS-21 in metastatic breast cancer
2005-000558-60Phase 2Completed
- Sponsor
- Pharmexa
- Start
- Feb 2005
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of HER-2 protein AutoVac in breast cancer, sponsored by Pharmexa. Primary endpoint: Clinical benefit rate. Started Feb 2005; status: completed.
02
Drugs
HER-2 protein AutoVac
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-000558-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000558-60.